Administration of 14C-tipranavir to subjects (n = 8) that received tipranavir/ ritonavir 500 mg/ 200 mg twice daily dosed to steady-state demonstrated that most radioactivity (median 82.3%) was excreted in faeces, while only a median of 4.4% of the radioactive dose administered was recovered in urine.